You are Trying to View a Premium ArticleDaily News You Can't Find Anywhere Else
Biosimilars Show Their Muscle as Emerging Pharmaceutical Phenomenon
Industry Segment: Pharmaceutical & Biotech | Word Count: 147 Words
Attachment: Biosimilar Heat Map, May 2018
SUGAR LAND--May 17, 2018--Researched by Industrial Info Resources (Sugar Land, Texas)--Almost the same, but not quite--a biosimilar is just that, similar but not equal to an original biological drug. Unlike generics, biological drugs are too complex be duplicated. And the market for biosimilars is definitely worth watching. Industrial Info is tracking nearly $2 billion worth of active biosimilar facility projects worldwide.
This Premium Article can be purchased individually or as part of a subscription
Subscribe Now! All Fields Required...
- Industrial Info's 2019 Outlook Chronicles the Winds of Change
- Spending Index Shows Impact of Chemical Mega Projects
- Global Pharma-Bio Industry Could See $11 Billion in Fourth-Quarter Project ...
- Novartis Accelerates Alcon Spinoff
- North America to See More than $22 Billion in 2019 Pharma/Bio Capital Proje...
- Current Economic Indicators
- Free Daily Industrial Articles
- Monthly Industrial Newsletter
- IIR's Disaster Impact Tracker